We are a motivated team from Latvia, the Netherlands and the UK that has formed around the Latvian Startup Exponential Technologies Ltd.. Exponential Technologies Ltd. was incorporated in 2019 and has already a stable stream of revenue. Our main partner is Evonik Industries, with whom we have several pilot projects running, test new applications of our software and improve it constantly.
6 months from now, when the first vaccines for COVID-19 are tested and approved, the fight is not over. It can take up to 12 months for the vaccine production to reach full capacity and produce the required 1-2 billion doses of the vaccine. Already now, the antibody tests need reagents produced by bioreactors and the global production is by far not at its maximum. We can reduce the time for the production scaling from months to weeks and save tens of thousands of lives.
What it does
xT BioE uses Design of Experiments techniques combined with unique, small data AI algorithms to help optimize bioreactors and other machine and mixture recipes, e.g. for the nutrition mixture used in a bioreactor. Additionally, we use a technique called data synthesis that helps to built new processes on data of existing processes, which allows the faster scaling between bioreactors of different size.
How we built it
Challenges we ran into
We need to understand better the processes and work flow while working with bioreactors to improve our GUI and make it easier for the user to adapt to the new software. We are also searching partners for testing, validation and feedback. Of course, we need also investment or public funding to bring the project to the next level.
Accomplishments that we're proud of
The core algorithm, in the form of the software xT smart_DoE, is also tested and in use by our partner Evonik Industries. We were under the 6 winners of the Data Natives #HackCorona hackathon and place 6 at Hackforce Latvia #HacktheCrisis hackathon. During this hackathon we built an amazing team and could grow our network.
What we learned
We met amazing people so far, found new partners and friends and could improve our software thanks to the input and mentorship we have received so far. We have learned a lot about the technological and the business processes and about the vaccine market itself. This will be very helpful in the future.
What's next for xT BioE
We need to further simplify our software, find additional partners for testing and validation and get funding to bring the project to the next level.